Alteogen
   
  22 DEC 2016 Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
  Poster : 관리자     Date : 17-02-23 17:20     Hit : 94    
   http://www.theinvestor.co.kr/view.php?ud=20161222000678 (22)
DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.

The biosimilar is scheduled to enter phase 3 clinical trials in 2017.

By Jung Min-kyung (mkj1105@heraldcorp.com)